Melioidosis is endemic throughout Southeast Asia and northern Australia. Caused by the environmental gram-negative bacillus *Burkholderia pseudomallei*, melioidosis can manifest as bacteremia, abscesses, or pneumonia. A case-fatality rate of \>50% has been reported ([@R1]).

Australia, Thailand, and Singapore have the most reported cases of melioidosis worldwide ([@R2]). The geographic, climatic, and infrastructural landscapes of these 3 countries differ vastly. The population demographics and ease of accessibility to healthcare also differ and may influence disease manifestations and outcomes. Epidemiologic case studies from Singapore are limited ([@R3]). We describe the latest epidemiologic findings based on national melioidosis surveillance data for 2003--2014.

The Study
=========

Melioidosis is a notifiable condition in Singapore. The laboratory and clinical criteria for notification are defined by the Ministry of Health, Singapore ([@R4]). Our study comprised all cases reported by medical practitioners and microbiology laboratories during 2003--2014. Public health officers collected demographic and clinical details of persons with notified cases using a standardized template. The data were extracted from the Ministry's Communicable Disease Surveillance system ([@R5]). We used a Poisson regression model, offset for population, to fit the annual melioidosis incidence to measure overall trend. A binomial generalized linear model with identity link was used to quantify temporal changes in the absolute proportion of melioidosis cases having each co-morbidity. We conducted a binomial test of whether the prevalence of comorbidities equaled that of the general population; the latter was derived from the last published National Health Survey 2010 ([http://www.moh.gov.sg/content/moh_web/home/Publications/Reports/2011/national\_ health_survey2010.html](http://www.moh.gov.sg/content/moh_web/home/Publications/Reports/2011/national_%20health_survey2010.html)) for persons 50−59 years of age (for diabetes and hypertension) and 40−54 years of age (for renal impairment). Analyses were performed with R Statistical Software version 3.3.1 (<https://www.r-project.org/>).

During the 12 years studied, notifications were received for 614 (range 31--96 annually) melioidosis cases ([Table](#T1){ref-type="table"}). The mean age of patients was 51.4 years; most (84.0%) patients were males. Most (72.1%) cases occurred in patients [\>]{.ul}45 years of age. The overall incidence of melioidosis was 1.1 per 100,000 population; incidence was highest among Malay and Indian populations (2.4 and 2.1/100,000, respectively). The most common manifestations of melioidosis were *B. pseudomallei* bacteremia (60.3%), abscesses (40.7%), and pneumonia (33.1%). Among the co-morbidities reported ([Table)](#T1){ref-type="table"}, diabetes (56.7%) and renal impairment (15.3%) had significantly higher prevalence among persons with melioidosis than among the general population of approximately the same age (19.3%, p\<0.001 for diabetes; 2.0%, p\<0.001 for renal impairment). In contrast, hypertension prevalence was consistent between melioidosis patients and the general population (35.5% vs. 31.9%; p = 0.057).

###### Demographic characteristics of patients with melioidosis, Singapore, 2003--2014\*

  Characteristic                      2003       2004        2005        2006       2007        2008        2009       2010        2011       2012      2013       2014       Total (%)†
  ----------------------------------- ---------- ----------- ----------- ---------- ----------- ----------- ---------- ----------- ---------- --------- ---------- ---------- -------------
  No. cases                           42         96          74          59         57          60          37         58          34         31        34         32         614
  Patient age, y                                                                                                                                                              
  Mean                                52.6       51.3        51.2        50.6       56.9        49.6        54.1       55          46.1       45.9      53.7       50         
  Minimum                             19         7           0           14         9           3           13         10          8          12        9          13         
  Maximum                             82         91          95          85         87          77          83         87          77         76        88         83         
  Sex                                                                                                                                                                         
  F                                   6          15          9           13         7           9           8          13          6          1         10         1          98 (16.0)
  M                                   36         81          65          46         50          51          29         45          28         30        24         31         516 (84.0)
  Incidence by race‡                                                                                                                                                          
  Chinese                             0.9        2.3         1.3         1.3        0.9         1.3         0.7        1           0.5        0.4       0.5        0.4        1.0§
  Malay                               2          2.9         4.1         2.2        3.5         2.8         0.8        3.2         1.6        1.8       2.3        1.2        2.4§
  Indian                              0.7        3.8         3.2         2.2        4.5         2.5         1.5        0.6         1.1        1.4       1.1        2.3        2.1§
  Comorbidity                                                                                                                                                                 
  Diabetes mellitus                   19         61          43          31         33          39          19         38          20         15        18         12         348 (56.7)
  Hypertensive   disease              10         29          23          18         27          27          8          21          17         10        13         15         218 (35.5)
  Hyperlipidemia                      1          2           10          7          4           11          2          22          4          5         7          12         87 (14.2)
  Ischemic heart   disease            3          19          5           10         4           4           1          3           2          1         3          5          60 (9.8)
  Chronic liver   disease/cirrhosis   0          4           1           1          1           1           0          0           1          0         0          0          9 (1.5)
  Neoplasm                            0          0           5           34         0           0           0          5           0          1         0          0          45 (7.3)
  Renal impairment                    9          23          11          10         13          12          3          3           3          1         3          3          94 (15.3)
  Anemia                              1          3           4           1          2           0           0          0           0          0         1          0          12 (2.0)
  Tuberculosis                        0          10          5           0          2           0           0          2           0          1         1          0          21 (3.4)
  COPD                                0          2           1           1          1           1           0          0           0          0         0          0          6 (1.0)
  Asthma                              0          4           6           1          1           2           0          2           1          1         0          0          18 (2.9)
  No. deaths, %                       6 (14.3)   25 (26.0)   12 (16.2)   9 (15.3)   12 (21.1)   12 (20.0)   5 (13.5)   14 (24.1)   6 (17.6)   2 (6.5%   8 (23.5)   2  (6.3)   113  (18.4)

\*Data extracted from (*5,9)*. COPD, chronic obstructive pulmonary disease. †Values are no. (%) unless otherwise indicated. ‡These are the standard reported races/ethnicities in Singapore. Incidence is per 100,000 population. §Mean.

During 2003--2014, melioidosis incidence decreased by 10% annually (incidence rate ratio 0.900; 95% CI 0.878--0.923; p\<0.001). The overall death rate was 18.4% and decreased by 12.3% annually (incidence rate ratio, 0.877; 95% CI 0.826--0.931; p\<0.001) ([Figure 1](#F1){ref-type="fig"}). Among melioidosis patients, there was a borderline declining trend in *B. pseudomallei* bacteremia cases annually (absolute risk reduction \[ARR\] 1.1%; 95% CI −2.3% to 0.1%; p = 0.076). However, the death rate for bacteremic patients did not change (ARR 0.4%; 95% CI −1.2% to 0.4%; p = 0.355) ([Figure 2](#F2){ref-type="fig"}, panel A). In contrast, melioidosis patients with pneumonia decreased from a peak of 56 cases in 2004 to no cases in 2014 (ARR 5.1%; 95% CI −5.6% to −4.6%; p\<0.001), accompanied by an ARR of 1.5% in mortality annually (95% CI −1.9% to −1.1%; p\<0.001) or 18% reduction in death during the 12-year period ([Figure 2](#F2){ref-type="fig"}, panel B).

![Annual incidence of melioidosis per 100,000 persons, Singapore, 2003--2014.](16-1449-F1){#F1}

![Melioidosis trends, Singapore, 2003--2014. A) Annual incidence of *Burkholderia pseudomallei* bacteremia and bacteremia-related deaths per 100 melioidosis cases. B) Annual incidence of melioidosis patients with pneumonia and pneumonia-related death per 100 melioidosis patients. C) Annual incidence of *B. pseudomallei* abscesses per 100 melioidosis patients. Local abscesses as per superficial or cutaneous, and deep abscess as per deep organ (primarily liver, spleen and prostate). D) Annual incidence of diabetes and diabetes-related death per 100 melioidosis patients.](16-1449-F2){#F2}

The annual incidence of *B. pseudomallei* abscesses was unchanged during 2003--2014, but the number of patients with deep abscesses (primarily liver, spleen, or prostate) increased (absolute risk increment 1.7% annually; 95% CI 0.7%--2.8%; p = 0.001) or 20.4% increment over 12 years ([Figure 2](#F2){ref-type="fig"}, panel C). We saw no evidence of a change in the prevalence of diabetes among persons with melioidosis (ARR 0.7%; 95% CI −1.9% to 0.5%; p = 0.277), although there was an ARR of 0.9% in mortality annually (95% CI −1.5% to −0.4%; p = 0.002) or 10.8% reduction over 12 years, for this at-risk patient group ([Figure 2](#F2){ref-type="fig"}, panel D).

This study, comprising one of the largest melioidosis patient cohorts thus far, yielded some unanticipated disease trends from Singapore. Foremost was the decreasing melioidosis incidence, in the context of declining *B. pseudomallei* bacteremia cases and, more significantly, the steady decrease in pneumonia.

By contrast in Australia and Thailand, melioidosis numbers stayed constant or increased ([@R6]). Pneumonia continued to feature prominently in 50% of the cases in these countries ([@R7]). It would be reasonable to theorize that pneumonia would be the predominant feature following inhalation of aerosolized *B. pseudomallei* after rainfall ([@R8]). Several groups have reported the association between rainfall, humidity, and water exposure with melioidosis ([@R9],[@R10]). In equatorial Singapore, however, rainfall patterns have not changed recently. In addition, our analysis of rainfall and humidity during the corresponding study period found these climatic variables to be constant on a yearly scale (rainfall, p = 0.846; humidity, p = 0.815). Hence, climate is unlikely to be related to the decline in disease incidence.

Soil, in particular anthrosol and acrisol soil, encountered in irrigated agriculture, has been suggested as a likely reservoir for *B. pseudomallei* ([@R10]). Consequently, urbanization leading to reduction of agricultural or rural land areas ought to align with a lower incidence of melioidosis. However, the developed island state of Singapore already had reached 100% urbanization by the early 1990s ([@R11]); thus, urbanization could not have been the primary factor for this decreasing incidence after 2003.

Conversely, water sanitization, storm/rainwater drainage, and flood reduction have remained a major focus of ongoing infrastructural improvements of the Singapore government through the 2000s to now. The national water strategy entails a complex system encompassing optimized drainage and collection, followed by water treatment intended for consumption and use. Flood risk is managed through design and implementation of state-of-the-art water drainage systems and flood-protection measures for public infrastructures ([@R12]). Together with a national flood alert response plan, these measures potentially minimize direct rain or contaminated water exposure and aerosol inhalation risk; thus, they are plausible factors to account for the overall melioidosis and pneumonia case reductions, but further study is needed to investigate this possibility.

We did not anticipate the 20.4% increase of *B. pseudomallei* deep organ abscesses during the study period. We theorized that it might partly be explained by compromised host immunity to *B. pseudomallei*, attributable to the progressively higher prevalence of diabetes in Singapore (than in Australia and Thailand) ([@R13]). Specifically in the context of abscess development, diabetic tissue macrophages impair *B. pseudomallei* killing capacity and an impaired interleukin IL12--interferon-γ response had been implicated ([@R14]). Conversely, melioidosis-associated deaths in patients with diabetes had decreased by 10.8% during our study period. This improvement in outcome might have found its roots in the drive for optimization of diabetes care at the public health level in Singapore in recent years ([@R15]).

Conclusions
===========

The overall death rate from melioidosis in Singapore was 18.4%, similar to that in the Northern Territory of Australia (14%). In both locations, these rates were attained on the background of similar standards and accessibility to healthcare and a low threshold for institution of treatment for melioidosis in accordance with recommendations ([@R1]). As efforts continue to further optimize clinical outcomes in acute melioidosis, our experience from Singapore for 2003--2014 suggests that acquisition of melioidosis and pneumonia may be curtailed through enhanced environmental and water management incorporating countrywide infrastructural improvements. In addition, enhanced management of the at-risk cohort of persons with diabetes also might prove pivotal in reducing disease.
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